Pharmafile Logo
Pharmafocus logo
Advanced Search

orion

Showing 5 posts of 5 posts found.

Third application for Orion’s prostate cancer drug submitted by partner Bayer

September 23, 2024
Bayer, Cancer, Oncology, orion, prostate cancer

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …

News
shutterstock_159488225

Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer

January 31, 2020
Medical Communications, Research and Development Bayer, orion, pharma

Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen …

News
fda2outsideweb

Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019
Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …

News

Bayer, Orion to start Phase III trials for prostate cancer drug

June 3, 2016
Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research

German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …

News

Medea wins European sedative account

January 4, 2010
Medical Communications Medea, orion, sedative

Medical communications agency Medea Communications has landed a brief to prepare the ground for a new sedative from Finnish company …

News
The Gateway to Local Adoption Series

Latest content

Sandoz launches two new bone disease biosimilars in Europe

December 3, 2025

Faron Pharmaceuticals appoints Jurriaan Dekkers as Chief Financial Officer

December 3, 2025

Medicus Pharma shares updates on basal cell carcinoma trials

December 2, 2025

Arnold & Porter appoints George Jenkins as partner

December 2, 2025

Safeguarding health and well-being for employees – the value of occupational health services

December 1, 2025